-
Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation
Friday, October 30, 2020 - 8:22pm | 321Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst. The Aldeyra Analyst: Kelly Shi initiated coverage of Aldeyra shares with a Buy rating and $24 price target. The Aldeyra Thesis...